Send to a Friend
Tayside Flow Technologies Ltd
| Parent Company | N/A |
| Product Range | vascular valves |
| Operation | Tayside Flow Technologies Ltd (TFT) is focused on the research, development and early stage commercialisation of cardio-vascular devices based on a new understanding of blood flow dynamics - Spiral Laminar Flow (SLF™ technology). The cardiovascular market is estimated at £11bn ($18bn equivalent) worldwide with annual growth rates of 10%. This innovative technology is based on modification of the physical properties of commercially available synthetic graft and stents, which will reduce downstream turbulence and wall pressure, resulting in a reduction in neo-intimal hyperplasia and the occurrence and rate of restenosis. The spiral laminar flow (SLF™) platform technology developed by TFT will be applied to a number of cardiovascular medical devices markets. The initial targets for SLF™ technology are large diameter peripheral vascular graft, peripheral and coronary stents and small diameter vascular grafts (peripheral and coronary). These markets were selected due to their significant size, growth potential and the demand for novel approaches to address unmet clinical needs. |
| MD | Anthony Odell |
| Contact | Dr Graeme Houston, Director |
| Address | unit 22 Prospect Business Centre Gemini Crescent Dundee Tech Park Dundee DD2 1TY |
| Phone | 01382 598532 |
| Fax | 01382 598528 |
| tft@tayflow.com | |
| Web | www.tayflow.com |
| Nationality | N/A |
| Employees | N/A |
| Turnover | N/A |
